Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 61

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 61
---
 products and therapies in conjunction with our scientific advisory board. Currently, we own 34 patents.
A summary of the number of patents, patent types and jurisdictions in listed in the table below. Once converted to the complete/PCT stage,
the provisional patents will also be applicable to all PCT contracting states. International search reports and written opinions of the
International Search Authority have confirmed that the key claims in our filed Patent Cooperation Treaty applications are novel and inventive
and that the invention meets the requirements of industrial applicability. The preparation of the International Search Report (ISR) and
International Search Opinion (ISO) for PCT applications is one of the main procedural steps of the international phase of the Patent Cooperation
Treaty (PCT). The purpose of conducting the searches at the international phase is to identify the relevant prior art and for the International
Searching Authority to establish a preliminary opinion as to whether the claims are novel, involve an inventive step and are industrially
applicable. While the ISR and the ISO are non-binding, in the sense that national patent offices are not obliged to accept any finding
of the International Searching Authority, these reports often represented a useful guide in relation to the patentability of the subject
matter claimed in the PCT application.

In the context of the PCT
applications that cover our product candidates, the International Searching Authority is the Australian Patent Office. Accordingly, the
opinion expressed in the ISR / ISO for each of these PCT applications is based on searches that have been conducted by Australian Patent
Examiners.

In addition to pursing patent
protection for all of our assets, we rely on unpatented trade secrets, know-how and other confidential information as well as proprietary
technological innovation and expertise that are protected in part by confidentiality and invention assignment agreements with our employees,
advisors and consultants.

Patent matters in biotechnology
are highly uncertain and involve complex legal and factual questions. The availability and breadth of claims allowed in biotechnology
and pharmaceutical patents cannot be predicted. Statutory differences in patentable subject matter may limit the scope of protection we
can obtain on some or all of our licensed inventions or prevent us from obtaining patent protection either of which could harm our business,
financial condition and results of operations. Since patent applications are not published until at least 18 months from their first filing
date and the publication of discoveries in the scientific literature often lags behind actual discoveries, we cannot be certain that we,
or any of our licensors, were the first creator of inventions covered